

The Journal of Organic Chemistry

VOLUME 55, NUMBER 10

MAY 11, 1990

© Copyright 1990 by the American Chemical Society

Communications

Antineoplastic Agents. 190. Isolation and Structure of the Cyclopeptide Dolastatin 14¹

George R. Pettit,* Yoshiaki Kamano, Cherry L. Herald, Claude Dufresne, Robert B. Bates,[†] Jean M. Schmidt, Ronald L. Cerny,[‡] and Haruhisa Kizu[§]


Cancer Research Institute and Department of Chemistry, Arizona State University, Tempe, Arizona 85287-1604, Department of Chemistry, University of Arizona, Tucson, Arizona 85721, Midwest Center for Mass Spectrometry, Department of Chemistry, University of Nebraska, Lincoln, Nebraska 68588-0362, and School of Pharmacy, Hokuriku University, Kanazawa-shi 920-11, Japan

Received December 13, 1989

Summary: The Indian Ocean sea hare *Dolabella auricularia* has been found to contain a novel cytostatic (PS ED₅₀ 0.022 µg/mL) cyclopeptide designated dolastatin 14. Structure 1 was assigned dolastatin 14 and was deduced primarily by a series of 2D NMR studies at high field (400 MHz).

The auriculate rhinophores (sensory tentacles resembling a hare's ears) prominent as appendages on sea hares (Aplysiidae family) may be used for tasting. If those organs are also responsible for selection of *Dolabella auricularia*'s (Indian Ocean) most impressive array² of antineoplastic and cytostatic constituents (and/or their biosynthetic precursors), unraveling the biochemical mechanisms involved would be quite enlightening. Discovery of cyclopeptides dolastatins 11, 12, and 15 and assignment of structures suggested possible dietary sources among the blue-green algae.^{2a-d} We have now found *D. auricularia* to contain another new and structurally intriguing cytostatic cyclopeptide designated dolastatin 14 (1) that may also be of blue-green algae origin. The very productive investigations of these little-explored microorganisms by Moore and colleagues have led to the isolation of interesting cyclopeptides with potentially important biological properties, such as the calcium antagonist scytonemin A.³

Dolastatin 14 was found to inhibit cell growth of the NCI murine P388 lymphocytic leukemia (PS system) with ED₅₀ 0.022 µg/mL. After the isolation of dolastatin 13 ((6 × 10⁻⁸)% yield from 1000 kg of wet sea hare), we explored by bioassay (PS) directed separation minor fractions near dolastatin 10 which led to pure dolastatin 14 (1) as an



DOLASTATIN 14

amorphous solid (12.0 mg total, (1.2 × 10⁻⁷)% yield) from methanol: mp 123–125 °C; [α]_D²⁴ -146° (c = 0.14, CH₃OH); TLC (R_f 0.35 in 90:10:0.8 CH₂Cl₂-CH₃OH-H₂O); UV (CH₃OH) λ_{max} 211 (ε 23 420) and 262 (ε 14 160) nm; IR (NaCl plate) ν_{max} 3320, 2963, 2930, 2875, 1732, 1670, 1640,

(1) In commemoration of Professor Carl Djerassi's 65th birthday. For contribution 189 consult: Pettit, G. R.; Singh, S. B.; Hogan, F.; Lloyd-Williams, P.; Herald, D. L.; Burkett, D. D.; Clewlow, P. *J. J. Am. Chem. Soc.* **1989**, *111*, 5463–5465.

(2) (a) Pettit, G. R.; Kamano, Y.; Dufresne, C.; Cerny, R. L.; Herald, C. L.; Schmidt, J. M. *J. Org. Chem.* **1989**, *54*, 6005–6006. (b) Pettit, G. R.; Kamano, Y.; Herald, C. L.; Dufresne, C.; Cerny, R. L.; Herald, D. L.; Schmidt, J. M.; Kizu, H. *J. Am. Chem. Soc.* **1989**, *111*, 5015–5017. (c) Pettit, G. R.; Kamano, Y.; Kizu, H.; Dufresne, C.; Herald, C. L.; Bontems, R.; Schmidt, J. M.; Boettner, F. E.; Nieman, R. A. *Heterocycles* **1989**, *28*, 553–558. (d) Pettit, G. R.; Kamano, Y.; Herald, C. L.; Tuinman, A. A.; Boettner, F. E.; Kizu, H.; Schmidt, J. M.; Baczynskyj, L.; Tomer, K. B.; Bontems, R. *J. Am. Chem. Soc.* **1987**, *109*, 6883–6885. (e) Pettit, G. R.; Kamano, Y.; Fujii, Y.; Herald, C. L.; Inoue, M.; Brown, P.; Gust, D.; Kitahara, K.; Schmidt, J. M.; Doubek, D. L.; Michel, C. *J. Nat. Prod.* **1981**, *44*, 482–485.

(3) Carter, D. C.; Moore, R. E.; Mynderse, J. S.; Niemczura, W. P.; Todd, J. S. *J. Org. Chem.* **1984**, *49*, 236–241.

*Department of Chemistry, University of Arizona.

[†]University of Nebraska.

[§]Hokuriku University.

Table I. Dolastatin 14 Correlated ^{13}C and ^1H NMR Assignments in Dichloromethane- d_2 Solution^a

structure assignment	^{13}C	chemical shift, ppm	^1H mult (J , Hz)	structure assignment	^{13}C	chemical shift, ppm	^1H mult (J , Hz)
2	171.0			18b	137.7		
3	55.8	4.82 q (7.0)		18c	129.9 × 2	7.22 m	
3a	16.1	1.45 d (7.0)		18d	128.6 × 2	7.21 m	
4a	29.9	2.75 s		18e	126.9	7.19 m	
5	169.4			19a	31.1	3.11 s	
6	49.7	5.77 dd (9.3, 5.3)		20	172.9		
6a	35.5	2.37 dd (15.3, 5.3)		21	55.2	4.65 t (9.9)	
		2.99 dd (15.3, 9.3)		21a	30.8	1.95 d heptet (9.9, 6.6)	
6b	172.1			21b	18.6	0.90 d (6.7)	
6c		5.25 brs, 5.75 ^b		21c	19.1	0.64 d (6.5)	
7a	30.5	2.93 s		22		6.01 d (9.9)	
8	171.6			23	169.3		
9	57.6	4.66 (dd (8.8, 4.0)		24	128.4		
9a	28.7	1.67 m, 2.02 m		24a	12.9	1.88 (2.2)	
9b	25.1	1.67 m, 1.87 m		25	134.7	6.70 dq (11.2, 2.2)	
9c	47.7	3.52 m, 3.68 m		26	127.8	6.35 dd (14.9, 11.2)	
11	168.6			27	138.0	5.99 ddd (14.9, 8.8, 6.1)	
12	60.1	4.89 d (10.8)		28	37.1	2.30 m, 2.48 m	
12a	27.2	2.08 d heptet (10.8, 6.7)		29	80.0	3.27 m	
12b	18.1	0.50 d (6.8)		29a	56.9	3.32 s	
12c	19.8	0.88 d (6.5)		30	34.4	1.47 m	
13	30.4	2.64 s		31	29.7	2.05 m	
14	170.3			32	131.2	5.44 dt (15.1, 6.1)	
15	58.9	5.01 d (10.7)		33	130.8	5.38 dt (15.1, 6.1)	
15a	27.9	2.15 d heptet (10.7, 6.7)		34	33.1	2.02 m	
15b	18.5	0.72 d (6.8)		35	26.6	1.30 m	
15c	19.7	0.78 d (6.5)		36	35.6	1.37 m, 1.63 m	
16a	29.9	2.67 s		37	73.1	4.79 m	
17	169.6			37a	19.8	1.20 d (6.1)	
18	55.0	5.74 dd (8.4, 7.0)					
18a	35.6	2.83 dd (13.7, 7.0)					
		3.25 dd (13.7, 8.4)					

^aResidual CH_2Cl_2 as internal reference (δ 5.32). ^bOverlapping signal.

1510, 1455, 1405, 1360, 1315, 1100, 785, and 700 cm^{-1} ; high-resolution SP-SIMS⁴ 1089.7009 $[\text{M} + \text{H}]^+$, $\text{C}_{59}\text{H}_{93}\text{N}_8\text{O}_{11}$ requires $[\text{M} + \text{H}]$ 1089.6964. Amino acid analyses suggested the presence of valine and proline.

In contrast to our prior experience with utilizing collision-activated decomposition (MS/MS) of HREI ions from dolastatin-type peptides to assist in structural elucidation, the mass spectral fragmentation of dolastatin 14 (1) gave primarily obtuse results. However, an unequivocal structure (1) for dolastatin 14 was eventually deduced by combining various high-field (400 MHz) NMR techniques that included ^1H , ^1H COSY, ^1H , ^{13}C COSY (consult Table I), and ^1H , ^1H -relayed COSY.⁵ By means of these methods the new hydroxy hexadecenoic acid (herein named dolatrienoic acid) and amino acid units were ascertained. Two of the olefin segments of dolatrienoic acid were clearly *E* as the respective vinyl protons were coupled with $J = 15$ Hz. The *E* configuration for the trisubstituted double bond was derived from the very large ^1H - ^{13}C NOE difference experiment value involving the C-24a methyl protons and the proton at C-26.

The sequence of dolastatin 14 components was established primarily by results of COSY, HETCOR, NOE, and heteronuclear multiple bond correlation (HMBC)⁶ NMR experiments in methylene- d_2 chloride. The most difficult connectivity problems were solved as follows. Lack of an N-10 to C-11 connection in the HMBC spectra was circumvented by the strong NOE's observed in both directions between the protons at C-9c and C-12. In methylene- d_2 chloride the carbonyl group chemical shifts of C-23

and C-5 fell within 0.1 ppm of one another and did not allow an unambiguous linkage assignment in the ring system. However in acetone- d_6 the difference increased to 0.3 ppm, and their connections were then safely established using HMBC methods. When the C-6a proton absorbing at δ 2.99 was irradiated, strong NOE's were observed for both amide protons at N-6c, thereby locating this otherwise elusive amino group.

Based on our complete structure determinations for dolastatins 3,⁷ 10,^{12d} and 15,^{2a} the Phe, Pro, and Val amino acid units of dolastatin 14 may bear the usual *S* configuration. Conclusive evidence for these assumptions and chiral assignments for the N-Me-Ala, N-Me-Asn, and dolatrienoic acid units will have to await larger scale reisolation and/or synthesis of dolastatin 14. Present biological results for this extraordinary cyclodepsipeptide indicate such future efforts will be quite productive.

Acknowledgment. With pleasure we thank for financial support the NCI Outstanding Investigator Grant CA-44344-01A1, Grants CA-16049-05-12 awarded by the NCI, DHHS, the Fannie E. Rippel Foundation, the Robert B. Dalton Endowment, Eleanore W. Libby, The Waddell Foundation (Donald Ware), the Arizona Disease Control Research Commission, Herbert K. and Dianne Cummings (The Nathan Cummings Foundation, Inc.), Polly J. Trautman, and Lotte Flugel. For other assistance we thank Drs. F. E. Boettner and R. A. Nieman, Messrs. P. L. Daschner and L. Williams, NSF Grant CHE-8409644, and the NSF Regional Instrumentation Facility in Nebraska (Grant CHE-8620177).

(4) (a) Holzapfel, C. W.; Pettit, G. R.; Cragg, C. M. *J. Nat. Prod.* **1985**, *48*, 513-522. (b) Pettit, G. R.; Holzapfel, C. W.; Cragg, G. M.; Herald, C. L.; Williams, P. *J. Nat. Prod.* **1983**, *46*, 971-922.

(5) Bax, A.; Drobny, G. *J. Magn. Reson.* **1985**, *61*, 306.

(6) Bax, A.; Summers, M. A. *J. Am. Chem. Soc.* **1986**, *108*, 2094.

(7) Pettit, G. R.; Kamano, Y.; Holzapfel, C. W.; van Zyl, W. J.; Tuinman, A. A.; Herald, C. L.; Baczyński, L.; Schmidt, J. M. *J. Am. Chem. Soc.* **1987**, *109*, 7581-7582.